Biopharmaceutical company Entrada Therapeutics, Inc. (TRDA) announced Wednesday the completion of dosing for the first and second cohorts of its Phase 1 clinical trial, ENTR-601-44-101.
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $16.67, but opened at $15.90. Entrada Therapeutics shares last traded at $15.47, with a volume of 5,380 shares. Analyst Upgrades and Downgrades Separately, HC Wainwright reiterated a “buy” rating and […]
Entrada Therapeutics Inc TRDA shares are trading lower after the company announced updates on ENTR-601-44 in Duchenne Muscular Dystrophy. The FDA previously…
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,000 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $16.23, for a total transaction of $16,230.00. Following the completion of the sale, the chief executive officer now directly owns 246,279 […]